Trials / Completed
CompletedNCT00171418
Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs).
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 54 (planned)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Study to assess the effects of adding tegaserod to PPI therapy results in clinically meaningful improvement of GERD symptoms in patients with incomplete relief of symptoms on daily PPI therapy alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tegaserod |
Timeline
- Start date
- 2003-06-01
- Completion
- 2005-02-01
- First posted
- 2005-09-15
- Last updated
- 2008-01-28
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00171418. Inclusion in this directory is not an endorsement.